Alliances
Seattle-based clinical-stage biopharmaceutical company Lumen Bioscience is teaming up with Novo Nordisk to explore research and development opportunities within obesity, among other metabolic disorders.
Both MannKind and United Therapeutics entered into a global and exclusive licensing and collaboration agreement to develop and commercialize Tyvaso DPI.
The research collaboration will see the development of bispecific antibodies and CAR-T cell products.
The study drug is a once-daily, two-week therapy developed by Sage Therapeutics and Biogen for major depressive disorder (MDD) and postpartum depression (PPD).
Per the agreement, CRISPR will lead the research and development of the Friedreich’s ataxia program, while Capsida will shepherd the R&D for the ALS effort.
Half of these doses will be shared by the U.S., while the U.K. has committed another 100 million shots.
This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.
The collaboration agreement will see the development and commercialization of the target, TMEM175 involved in Parkinson’s disease and other neurodegenerative conditions.
Kojin launched with a $60 million Series A to focus on oncology and cell state biology led by Polaris Partners, Newpath Partners and Cathay Health.
The $7 billion transaction by Datavant with Ciox Health will be the nation’s largest “neutral and secure health data ecosystem.”
PRESS RELEASES